Pharma Focus Asia

Cellular Biomedicine Group Announces New Facility to Expand Research and Development and to Support Clinical Development

Thursday, October 03, 2019

Cellular Biomedicine Group, Inc., a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a lease agreement to build an approximately 22,000 square foot facility in Rockville, Maryland to augment its global research and development capabilities and to support clinical trials in the United States centering around both its liquid tumor and solid tumor candidates. The facility, when completed, will allow the development of new technology and preparation for clinical trials according to U.S. Food and Drug Administration (FDA) guidelines. The Company intends for the facility to have a capacity to accommodate early phases of CBMG's clinical trials for its liquid and solid tumor candidates.

"This new site is poised to foster strategic partnership, new innovations, and support the continued development of CBMG's cell therapy based immune-oncology assets in the US that have showed promise in early proof-of-concept trials," said Tony (Bizuo) Liu, Chief Executive Officer for the Company.  

The Rockville facility is strategically located in the heart of Maryland's life sciences center, on Medical Center Drive, an area commonly referred to as "DNA Alley."

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024